Alexey Aleshin

7.5k total citations
90 papers, 1.6k citations indexed

About

Alexey Aleshin is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Alexey Aleshin has authored 90 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Cancer Research, 48 papers in Oncology and 37 papers in Pathology and Forensic Medicine. Recurrent topics in Alexey Aleshin's work include Cancer Genomics and Diagnostics (70 papers), Genetic factors in colorectal cancer (35 papers) and Cancer Cells and Metastasis (15 papers). Alexey Aleshin is often cited by papers focused on Cancer Genomics and Diagnostics (70 papers), Genetic factors in colorectal cancer (35 papers) and Cancer Cells and Metastasis (15 papers). Alexey Aleshin collaborates with scholars based in United States, Japan and United Kingdom. Alexey Aleshin's co-authors include Richard S. Finn, Dennis J. Slamon, Minetta C. Liu, Stacey A. Cohen, Paul R. Billings, Himanshu Sethi, Meenakshi Malhotra, Shruti Sharma, Pashtoon Murtaza Kasi and Ekaterina Kalashnikova and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Alexey Aleshin

87 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alexey Aleshin United States	21	863	828	583	491	341	90	1.6k
Rabiul Islam United States	7	1.3k 1.5×	1.3k 1.5×	337 0.6×	649 1.3×	322 0.9×	8	2.1k
Hannah Y. Wen United States	24	823 1.0×	801 1.0×	268 0.5×	347 0.7×	551 1.6×	106	1.7k
S. Michael Rothenberg United States	22	737 0.9×	501 0.6×	403 0.7×	882 1.8×	201 0.6×	45	1.8k
Giorgia Migliardi Italy	18	719 0.8×	277 0.3×	352 0.6×	515 1.0×	180 0.5×	28	1.3k
Kazumi Nishino Japan	25	1.4k 1.6×	735 0.9×	1.6k 2.7×	661 1.3×	221 0.6×	164	2.3k
Ruth Riisnaes United Kingdom	15	497 0.6×	479 0.6×	667 1.1×	786 1.6×	198 0.6×	42	1.5k
Vicente Peg Spain	28	998 1.2×	1.3k 1.6×	451 0.8×	1.1k 2.2×	555 1.6×	79	2.4k
Jon Chung United States	25	1.0k 1.2×	677 0.8×	720 1.2×	765 1.6×	249 0.7×	109	2.0k
Ana Suárez‐Gauthier Spain	14	694 0.8×	833 1.0×	319 0.5×	1.1k 2.3×	260 0.8×	21	1.8k
Maja J.A. de Jonge Netherlands	19	848 1.0×	259 0.3×	420 0.7×	865 1.8×	195 0.6×	40	1.6k

Countries citing papers authored by Alexey Aleshin

Since Specialization

Citations

This map shows the geographic impact of Alexey Aleshin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexey Aleshin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexey Aleshin more than expected).

Fields of papers citing papers by Alexey Aleshin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexey Aleshin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexey Aleshin. The network helps show where Alexey Aleshin may publish in the future.

Co-authorship network of co-authors of Alexey Aleshin

This figure shows the co-authorship network connecting the top 25 collaborators of Alexey Aleshin. A scholar is included among the top collaborators of Alexey Aleshin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexey Aleshin. Alexey Aleshin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cutts, Rosalind, Matthew Beaney, M Robert, et al.. (2024). Association of post-operative ctDNA detection with outcomes of patients with early breast cancers. ESMO Open. 9(9). 103687–103687. 12 indexed citations

Powles, Thomas, Zoe J. Assaf, Viraj Degaonkar, et al.. (2023). Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. European Urology. 85(2). 114–122. 61 indexed citations

Loree, Jonathan M., Russell W. Madison, Christopher J. O’Callaghan, et al.. (2023). Feasibility of circulating tumor DNA (ctDNA) to guide organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II CCTG CO.28 trial.. Journal of Clinical Oncology. 41(4_suppl). 180–180.

Eroglu, Zeynep, Ekaterina Kalashnikova, Charuta C. Palsuledesai, et al.. (2023). Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer. 129(11). 1723–1734. 33 indexed citations

Lindskrog, Sia V., Karin Birkenkamp‐Demtröder, Iver Nordentoft, et al.. (2023). Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up. Clinical Cancer Research. 29(23). 4797–4807. 26 indexed citations

Kasi, Pashtoon Murtaza, Sakti Chakrabarti, Sarah Sawyer, et al.. (2022). BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. BMJ Open. 12(5). e060342–e060342. 9 indexed citations

Agostinetto, Elisa, Matteo Lambertini, Françoise Rothé, et al.. (2022). Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. JCO Precision Oncology. 6(6). e2200148–e2200148. 48 indexed citations

Huffman, Brandon M., Vasily N. Aushev, Joseph Chao, et al.. (2022). Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. JCO Precision Oncology. 6(6). e2200420–e2200420. 36 indexed citations

George, Thomas J., Greg Yothers, Anuradha Krishnamurthy, et al.. (2022). NSABP FC-12: A single-arm, phase II study to evaluate treatment with gevokizumab in patients with stage II/III colon cancer who remain ctDNA+ after curative surgery and adjuvant chemotherapy.. Journal of Clinical Oncology. 40(16_suppl). TPS3642–TPS3642. 1 indexed citations

10.

Magbanua, Mark Jesus M., Wen Li, Denise M. Wolf, et al.. (2021). Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. npj Breast Cancer. 7(1). 32–32. 33 indexed citations

11.

Taniguchi, Hiroya, Yoshiaki Nakamura, Daisuke Kotani, et al.. (2021). CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Science. 112(7). 2915–2920. 92 indexed citations

12.

Kasi, Pashtoon Murtaza, Sarah Sawyer, Michelle L. Munro, et al.. (2021). BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. BMJ Open. 11(9). e047831–e047831. 33 indexed citations

13.

Dhakal, Binod, Shruti Sharma, Svetlana Shchegrova, et al.. (2021). Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma.. Journal of Clinical Oncology. 39(15_suppl). 8029–8029.

14.

Anandappa, Gayathri, Naureen Starling, Ruwaida Begum, et al.. (2021). Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC).. Journal of Clinical Oncology. 39(3_suppl). 102–102. 27 indexed citations

15.

Kasi, Pashtoon Murtaza, Sarah Sawyer, Michelle L. Munro, et al.. (2020). 520TiP A multicenter study to evaluate the impact of circulating tumor DNA guided therapy (BESPOKE) in patients with stage II and III colorectal cancer. Annals of Oncology. 31. S459–S459. 2 indexed citations

16.

Iafolla, Marco, Cindy Yang, Scott Dashner, et al.. (2019). Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P).. Journal of Clinical Oncology. 37(15_suppl). 2542–2542. 7 indexed citations

17.

Aleshin, Alexey, Peter L. Greenberg, Bruno C. Medeiros, et al.. (2018). Abstract 3004: Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression. Cancer Research. 78(13_Supplement). 3004–3004. 1 indexed citations

18.

Finn, Richard S., Alexey Aleshin, & Dennis J. Slamon. (2016). Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Research. 18(1). 17–17. 268 indexed citations

19.

Aleshin, Alexey, et al.. (2010). p27Kip1 Mediates Addiction of Ovarian Cancer Cells to MYCC (c-MYC) and Their Dependence on MYC Paralogs. Journal of Biological Chemistry. 285(42). 32529–32538. 19 indexed citations

20.

Hyde, Jennifer, et al.. (2006). SNS-032 is a potent and selective inhibitor of CDK2, 7 and 9 and induces cell death by inhibiting cell cycle progression and the expression of antiapoptotic proteins. Cancer Research. 66. 491–491. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact